### 1 PFHpA alters lipid metabolism and increases the risk of metabolic dysfunction-associated

### 2 steatotic liver disease in youth—a translational research framework

- 3 **Authors:** Brittney O. Baumert<sup>\*1</sup>, Ana C. Maretti-Mira<sup>\*2</sup>, Zhenjiang Li<sup>1</sup>, Nikos Stratakis<sup>3</sup>, Yinqi
- 4 Zhao<sup>1</sup>, Douglas I. Walker<sup>4</sup>, Hongxu Wang<sup>1</sup>, Fabian Christoph Fischer<sup>5</sup>, Qiran Jia<sup>1</sup>, Damaskini
- 5 Valvi<sup>6</sup>, Scott M. Bartell<sup>7</sup>, Carmen Chen<sup>1</sup>, Thomas Inge<sup>8,9</sup>, Justin Ryder<sup>8,9</sup>, Todd Jenkins<sup>10</sup>,
- 6 Stephanie Sisley<sup>11</sup>, Stavra Xanthakos<sup>10</sup>, Rohit Kohli<sup>12</sup>, Sarah Rock<sup>1</sup>, Sandrah P. Eckel<sup>1</sup>, Michele
- 7 A. La Merrill<sup>13</sup>, Max M. Aung<sup>1</sup>, Matthew P. Salomon<sup>2</sup>, Rob McConnell<sup>1</sup>, Jesse Goodrich<sup>1</sup>, David
- 8 V. Conti<sup>1</sup>, Lucy Golden-Mason<sup>2</sup>, Lida Chatzi<sup>1</sup>

# 9 \*These authors contributed equally

- <sup>1</sup>Department of Population and Public Health Sciences, Keck School of Medicine, University of
- 11 Southern California, Los Angeles, CA, United States
- <sup>2</sup> USC Research Center for Liver Diseases, Division of Gastrointestinal and Liver Diseases,
- 13 Department of Medicine, Keck School of Medicine, University of Southern California, Los
- 14 Angeles, CA, United States
- <sup>3</sup> Barcelona Institute for Global Health, ISGlobal, Dr. Aiguader 88, 08003, Barcelona, Spain
- <sup>4</sup> Gangarosa Department of Environmental Health, Rollins School of Public Health, 1518 Clifton
- 17 Road, NE, Atlanta, GA, United States
- <sup>5</sup> Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston,
   RI 02881, United States
- <sup>6</sup> Department of Environmental Medicine and Climate Science, Icahn School of Medicine at
- 21 Mount Sinai, New York, NY, United States

- <sup>7</sup> Department of Environmental and Occupational Health, University of California, Irvine,
- 23 Irvine, CA, United States
- <sup>8</sup> Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL,
- 25 United States
- <sup>9</sup> Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States
- 27 <sup>10</sup> Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of
- 28 Cincinnati College of Medicine, Cincinnati, OH, United States
- 29 <sup>11</sup> Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States
- 30 <sup>12</sup> Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital Los Angeles, Los
- 31 Angeles, CA, United States
- 32 <sup>13</sup> Department of Environmental Toxicology, University of California, Davis, CA, United States

# 33 Funding

- 34 The results reported herein correspond to specific aims of grant R01ES030691 to Dr. Chatzi
- 35 from the National Institute of Environmental Health Science (NIEHS). Additional funding from
- 36 NIEHS supported Dr. Chatzi (R01ES029944, R01ES030364, U01HG013288, and
- 37 P30ES007048, European Union: The Advancing Tools for Human Early Lifecourse Exposome
- 38 Research and Translation (ATHLETE) project, grant agreement number 874583), Dr. Baumert
- 39 (R01ES030691, R01ES030364, and T32-ES013678), Dr. Goodrich (P30ES007048 and
- 40 U01HG013288), Dr. Aung (P30ES007048 and U01HG013288), Dr. Valvi (R01ES033688,
- 41 R21ES035148 and P30ES023515), Dr. Walker (R01ES030691, U2CES030859, and
- 42 R01ES032831), Dr. McConnell (P30ES007048, P2C ES033433), and Dr. La Merrill
- 43 (R01ES030364), Dr. Conti (R21ES029681, R01ES030691, R01ES030364, R01ES029944,

44	P01CA196569, and P30ES007048), Dr. Sisley (R01DK128117–01A1). Dr. Stratakis received		
45	funding from European Union's Horizon Europe research and innovation programme under the		
46	Marie Skłodowska-Curie Actions Postdoctoral Fellowships (101059245). Dr. La Merrill was		
47	additionally supported by the California Environmental Protection Agency (20-E0017). Dr.		
48	Sisley was additionally supported by Department of Agriculture (6250-51000-053). The Teen-		
49	LABS consortium is supported by cooperative agreements with the National Institute of Diabetes		
50	and Digestive and Kidney Diseases (NIDDK) through grants for a clinical coordinating center		
51	(UM1DK072493; Inge) and the Data Coordinating Center (UM1DK095710).		
52			
53	Corresponding author:		
54	Lida Chatzi, PhD, Department of Population and Public Health Sciences, University of Southern		
55	California, Keck School of Medicine of USC, 2001 N. Soto Street, Los Angeles, CA 90032,		
56	USA. chatzi@usc.edu		
57			
58	Conflict of interest disclosures.		
59	The authors declare that they have no conflicts of interest apart from Dr. Bartell who has		
60	provided paid expert assistance in legal cases involving PFAS exposed populations.		
61	Declaration of competing financial interests.		
62	All other authors declare they have no actual or potential competing financial interests.		
63	Human Subjects		

- 64 Ethics approval for this study was provided by the University of Southern California Institutional
- 65 Review Board (IRB protocols HS-19-00057). Prior to participation, written informed
- 66 assent/consent were obtained from participants and their guardians. The Teen–Longitudinal
- 67 Assessment of Bariatric Surgery (Teen–LABS) study
- 68 (<u>ClinicalTrials.gov</u> number, <u>NCT00474318</u>) was designed as prospective, multicenter,
- 69 observational study of consecutive cases of bariatric surgery offered to adolescents. The study
- 70 methodology has been previously described.

# 71 Acknowledgements

- 72 The authors would like to acknowledge the significant contributions made by all Teen-LABS
- rd study personnel as well as study participants. Additionally, the authors would like to
- 74 acknowledge the contributions made by Flemming Nielsen, PhD and Philippe Grandjean, MD,
- 75 PhD—both lead the laboratory analysis of plasma-PFAS of Teen-LABS participants.

# 77 Abstract

78 To address the growing epidemic of liver disease, particularly in pediatric populations, it is 79 crucial to identify modifiable risk factors for the development and progression of metabolic 80 dysfunction-associated steatotic liver disease (MASLD). Per- and polyfluoroalkyl substances 81 (PFAS) are persistent ubiquitous chemicals and have emerged as potential risk factors for liver 82 damage. However, their impact on the etiology and severity of MASLD remains largely 83 unexplored in humans. This study aims to bridge the gap between human and in vitro studies to 84 understand how exposure to perfluoroheptanoic acid (PFHpA), one of the emerging PFAS 85 replacements which accumulates in high concentrations in the liver, contributes to MASLD risk and progression. First, we showed that PFHpA plasma concentrations were significantly 86 87 associated with increased risk of MASLD in obese adolescents. Further, we examined the impact 88 of PFHpA on hepatic metabolism using 3D human liver spheroids and single-cell transcriptomics 89 to identify major hepatic pathways affected by PFHpA. Next, we integrated the *in vivo* and *in* 90 *vitro* multi-omics datasets with a novel statistical approach which identified signatures of 91 proteins and metabolites associated with MASLD development triggered by PFHpA exposure. In 92 addition to characterizing the contribution of PFHpA to MASLD progression, our study provides 93 a novel strategy to identify individuals at high risk of PFHpA-induced MASLD and develop 94 early intervention strategies. Notably, our analysis revealed that the proteomic signature 95 exhibited a stronger correlation between both PFHpA exposure and MASLD risk compared to 96 the metabolomic signature. While establishing a clear connection between PFHpA exposure and 97 MASLD progression in humans, our study delved into the molecular mechanisms through which 98 PFHpA disrupts liver metabolism. Our in vitro findings revealed that PFHpA primarily impacts 99 lipid metabolism, leading to a notable increase of lipid accumulation in human hepatocytes after 100 PFHpA exposure. Among the pathways involved in lipid metabolism in hepatocytes, regulation 101 of lipid metabolism by PPAR- $\alpha$  showed a remarkable activation. Moreover, the translational 102 research framework we developed by integrating human and in vitro data provided us 103 biomarkers to identify individuals at a high risk of MASLD due to PFHpA exposure. Our 104 framework can inform policies on PFAS-induced liver disease and identify potential targets for 105 prevention and treatment strategies. 106

- 107
- 108
- 109
- 110
- 111

### 112 Introduction

113 Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic liver disease (NAFLD)<sup>1</sup>, refers to a spectrum of liver disorders including the 114 115 metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic 116 steatohepatitis (NASH). A hallmark of MASLD is the fat accumulation (steatosis) in the liver due to chronic metabolic dysfunction<sup>2</sup>. MASLD management addresses long-term healthcare 117 118 needs and generates substantial economic burden<sup>3</sup>. The prevalence of MASLD in children has 119 been growing in recent years, paralleling the rise in childhood obesity and metabolic syndrome<sup>4,5</sup>. MASLD is now one of the most common chronic liver diseases in children 120 121 worldwide, affecting approximately 10% of children in the general population<sup>5</sup>. Among children 122 with overweight or obesity, the prevalence of MASLD is much higher, to an estimated of 30-40%<sup>4</sup>. Limited interventions are available for the improvement of MASLD in children <sup>6</sup>. Diet 123 124 restrictions, physical activity interventions and FDA-approved drugs including GLP-1 receptor agonists<sup>7</sup> have been used with limited success in adolescents with MASLD<sup>8</sup>. This highlights the 125 126 need for preventive measures, such as identifying and intervening on modifiable risk factors. 127 The traditional risk factors for MASLD, such as excess energy intake, sedentary lifestyle, and genetics, cannot fully explain the MASLD epidemic in children<sup>9</sup>. Moreover, emerging 128 129 evidence indicates that exposure to endocrine-disrupting chemicals can promote metabolic 130 changes that result in fatty liver disease - a hypothesis referred to as the 'Toxicant Fatty Liver Disease<sup>,10-12</sup>. Per- and polyfluorinated substances (PFAS), a large class of synthetic fluorinated 131 132 organic chemicals, are globally ubiquitous. These chemicals have been used in industrial 133 applications and consumer products, including water-repellent textiles, nonstick coatings, and food packaging products, for over 60 years<sup>13</sup>. PFAS have been detected in blood of over 99% of 134

135	individuals in the US. <sup>14,15</sup> Production of certain PFAS, such as perfluorooctane sulfonate (PFOS)
136	and perfluorooctanoate (PFOA), was voluntarily phased-out in the U.S. during the 2000s, yet
137	their negative health effects remain a concern because of their long half-lives (1.8-6.2
138	years). <sup>14,16-18</sup> Consequently, newer PFAS variants, known as replacements, have been introduced,
139	featuring shorter biological half-lives, to mitigate environmental persistence. <sup>16</sup> However, many
140	of these replacements lack regulation and thorough testing regarding potential health risks,
141	particularly during crucial developmental stages.
142	Additional studies are needed to better understand the health effects of replacement
143	PFAS. Research has established that PFAS can accumulate in the human body and preferentially
144	accumulate in the liver <sup>19-21</sup> , where they can disturb several hepatic functions, especially lipid
145	metabolism <sup>18,22-24</sup> . An abundance of evidence exists based on concordance between experimental
146	and population findings that certain PFAS are hepatotoxic to humans and many studies point to
147	PFAS-induced lipid disruption <sup>22</sup> . Nevertheless, several gaps persist in the literature, such as a)
148	whether individuals classified as overweight/obese are more prone to PFAS-induced liver
149	toxicity, b) whether understudied PFAS compounds including replacement PFAS can induce
150	liver damage, and c) which metabolic pathways affected by PFAS are significant and indicative
151	of liver damage <sup>18,22,24,25</sup> .

We propose a translational research framework to connect scientific findings from human and in vitro studies, aiming to understand how PFAS contribute to MASLD progression (see Fig. 1). Our investigation focused on perfluoroheptanoic acid (PFHpA), a short-chain carboxylic PFAS compound found in high concentrations in the liver<sup>23</sup> which was strongly linked to MASLD risk and severity of disease in obese adolescents. Using an innovative approach, we assessed PFHpA's impact on liver metabolism in vitro by combining 3D human liver spheroids

- 158 with single-cell transcriptomics. This allowed us to identify the primary metabolic pathways
- 159 affected by PFHpA. Subsequently, we integrated multi-omic datasets from the human and in
- 160 vitro study using advanced statistical methods. Through this analysis, we identified protein and
- 161 metabolite signatures associated with MASLD development due to PFHpA exposure. Our study
- 162 presents a novel strategy to identify individuals at high risk of developing PFAS-induced
- 163 MASLD and to develop early intervention strategies.

# 165 **Results**

### 166 Human Study: PFHpA increases the risk for MASLD in adolescents – Insights into

### 167 Steatosis Severity and Disease Progression

- 168 The current project included 136 adolescents with severe obesity who underwent bariatric
- surgery. Based on liver biopsies fifty-five (40%) participants were categorized as non-MASLD,
- 170 51 (38%) as MASLD not MASH, and 30 (22%) as MASH. Among 8 PFAS congeners, plasma-
- 171 PFHpA (mean = 0.13 ng/mL, SD = 0.12 ng/mL) was the sole PFAS congener significantly
- associated with both MASLD and MASH (Fig. S1, Table S1). Among adolescents in the Teen-
- 173 LABS study, we observed 68% higher odds of MASLD per doubling of PFHpA (OR: 1.68, 95%

174 CI: 1.19, 2.37) (Fig. S1, Table S1). We observed a significant dose-dependent relationship with

- 175 PFHpA (p for trend=0.002), indicating a biological gradient in MASLD risk across exposure
- 176 octiles (Fig. 2b). Furthermore, PFHpA exhibited significant associations with several indicators
- 177 of disease severity, including the degree of steatosis (OR=1.61, 95% CI: 1.16, 2.24 for mild
- 178 steatosis and OR=1.88, 95% CI: 1.22, 2.89 for moderate steatosis), fibrosis (OR =1.49, 95% CI:

179 1.04, 2.14), and MASLD activity score (MAS) (OR=3.04, 95% CI: 1.78, 5.21). (Fig. 2c).

180

# Human Study: PFHpA Affects Lipid Metabolism, Oxidative Stress, and Inflammation in Adolescents

Using Metabolome-Wide Association Study (MWAS) and Proteome-Wide Association Study
(PWAS) approaches, we identified significant alterations in 51 metabolites and 55 proteins
significantly altered by PFHpA exposure (Fig. 3a & 3b). Ingenuity Pathway Analysis (IPA)
revealed the biological pathways affected by PFHpA (Fig. 3c & 3d). Specifically, pathways

187 related to inflammation were enriched, including the Inflammation pathway influenced by 188 altered metabolites, and the Inflammatory Response and Cell Movement of Dendritic Cells 189 pathways affected by altered proteins. We also observed an increase in the Synthesis of Reactive 190 Oxygen Species pathway by metabolites, underscoring the role of inflammation and oxidative 191 stress in PFHpA toxicity. Additionally, disruptions in lipid metabolism were evident, with 192 enrichment of pathways such as Synthesis of Lipid and Concentration of Lipid, indicating lipid 193 dysregulation as a potential consequence of PFHpA exposure. PWAS IPA analysis further 194 emphasized PFHpA's associations with immune response, showing enrichment in immunity-195 related pathways by PFHpA-associated proteins. These pathways include Recruitment of 196 Mononuclear Leukocytes, Formation of Lymphoid Tissue, Cell Proliferation of T Lymphocytes, 197 and Cell Death of Lymphatic System Cells.

198

### 199 In vitro study: PFHpA disturbs lipid metabolism in human liver spheroids.

200 To determine the involvement of PFHpA in MASLD progression, we performed an *in vitro* 201 assay to expose human liver spheroids comprised of human primary hepatocytes and non-202 parenchymal cells to PFHpA for 7 days in low-glucose media (Fig. 1b). Subsequent analysis 203 through single-cell RNA sequencing (scRNA-seq) revealed the transcriptomic alterations in the 204 cells composing the liver spheroids. Of note, we identified hepatocytes, T cells, Kupffer cells and 205 NK cells (Fig. 4a). B cells were detected in a very reduced number and therefore were not 206 included in the further analysis. Overall, we found that PFHpA exposure altered the expression 207 of 472 genes in liver spheroids, with 156 genes upregulated and 316 genes downregulated. 208 Analyzing the hepatic cell populations, we observed that hepatocytes and T cells exhibited the 209 most pronounced numbers of differentially expressed genes (DEGs), with 263 (137 up and 126

210 down) and 383 (98 up and 285 down) DEGs respectively (Fig. 4b). NK cells showed 26 DEGs 211 (19 up and 7 down) and Kupffer cells only showed the upregulation of 1 gene. Pathway analysis 212 using IPA highlighted a notable impact of PFHpA on liver metabolism. In the whole liver 213 spheroids, as well as the hepatocytes and T cells, we observed a substantial upregulation of 214 pathways involved in lipid metabolism (48%, 45%, and 40% respectively), amino acid 215 metabolism (21%, 18%, and 20% respectively), and detoxification pathways (14%, 14%, and 216 10% respectively) indicating a significant disturbance induced by PFHpA exposure (Fig. 4c-e). 217 Furthermore, PFHpA exposure led to the upregulation of peroxisome proliferator-activated 218 receptor alpha (PPAR- $\alpha$ ) activation and fatty acid oxidation in human hepatocytes (Fig. 4f). Most 219 pathways involved in hepatocyte lipid metabolism were related to lipid anabolism (lipogenesis), 220 with the upregulation of several lipid biosynthesis, including cholesterol. This observation was 221 confirmed by Nile Red imaging of spheroid lipid accumulation (Fig. 4g), which showed that 222 liver spheroids exposed to PFHpA significantly accumulate more lipids than control spheroids 223 (p=0.01) (Fig. 4h). Although PFHpA exposure also activates lipid metabolism in T cells, the 224 upregulated pathways were primarily related to nuclear hormone receptors activation, without a 225 direct impact on lipid biosynthesis as observed in hepatocytes (Fig. S2). These findings 226 underscore the pivotal role of PFHpA in disrupting lipid metabolism, particularly in hepatocytes, 227 shedding light on the potential PFHpA contribution to MASLD pathogenesis.

# Unveiling Biomarker Signatures for PFHpA-induced MASLD through Multi-omics Integration

We integrated data from the human and the in vitro studies to identify plasma biomarkers indicative of PFHpA-induced MASLD using the OmicsNet 2.0 platform. Specifically, our analysis combined 156 upregulated genes (GEX) from the in vitro study with 42 metabolites

(MWAS) and 28 proteins (PWAS) upregulated in the human study (Fig. 1c). OmicsNet 2.0 identified pathways showing significant overlap between GEX-MWAS and GEX-PWAS datasets. We identified a metabolomic signature of PFHpA-induced MASLD consisting of 19 metabolites involved in lipid metabolism, amino acid metabolism, nutrient uptake, energy metabolism, and vitamin and nucleic acid metabolism (Fig. 5b). Additionally, a proteomic signature was defined, comprising 6 proteins from pathways involved in lipid degradation, vitamin metabolism, immune response, detoxification, and cancer (Fig. 5c).

Next, we integrated these overlapping features in a latent unknown clustering with integrated data (LUCID) model to assess the association between PFHpA exposure, multi-omics signatures, and MASLD risk. <sup>26</sup> This approach categorized individuals into groups based on similarities across PFHpA exposure, proteome, metabolome signatures, and disease outcomes, focusing on disease risk rather than stratification.

245 Figure 6 illustrates the joint associations between PFHpA and two latent clusters (profiles) of 246 each omic layer (metabolome and proteome), identifying low and high MASLD risk clusters 247 using unsupervised LUCID and logistic regression models. PFHpA showed a stronger 248 association with the high-MASLD risk cluster characterized by proteins (OR = 2.73) compared 249 to its association with the low-risk cluster characterized by metabolites (OR = 1.05). Notably, 250 individuals in proteome profile 1 had significantly higher odds of MASLD (OR = 7.08) than 251 those in proteome profile 0, while individuals in metabolome profile 1 had lower odds of 252 MASLD (OR = 0.51) compared to those in metabolome profile 0. This designates metabolome 253 profile 0 and proteome profile 1 as high-risk multi-omic profiles.

Fig. 6b describes the high and low risk for MASLD groups of individuals by the clusters of metabolites and proteins that differentiate these risk groups. Notably, tryptophan,

glycochenodeoxycholic acid, and deoxycarnitine emerged as predominant metabolome features distinguishing high and low-risk profiles. Negative scaled values of metabolome features, with the exception of Trans-4-Hydroxy-L-Proline and 5-Aminovaleric acid, tended to correlate with a higher risk of MASLD. Conversely, positive scaled values of proteome features defined a higher risk of MASLD. Remarkably, HYAL1, F7, CA5A, C2, ADH4, and ACY1 exhibited similar scaled values ranging from 0.21 to 0.25 among high-risk profiles, while ranging from -0.63 to -0.52 among low-risk profiles.

### 263 Discussion

264 We demonstrated a significant link between exposure to PFHpA and the MASLD risk 265 and severity of disease, and further elucidated the molecular and cellular mechanisms underlying 266 this association. The Teen-LABS study is a highly unique resource—providing the opportunity 267 to investigate the relationship between PFAS and MALD using a cohort with largely extreme 268 obesity and consistent availability of well characterized liver biopsies for the diagnosis of MASLD<sup>27</sup>. Like other PFAS compounds, PFHpA is persistent in the environment and has been 269 270 detected in water, air, soil, and biota worldwide. The half-life of PFHpA in humans is approximately 2 months<sup>28</sup>. PFHpA can be formed as a minor degradation product of long-chain 271 PFAS<sup>29-31</sup>. Although PFHpA has gained attention in recent years, the relatively few studies 272 273 investigating it may reflect a combination of factors including historical research priorities, 274 technical challenges, and resource limitations. While previous research has established a 275 connection between PFHpA exposure, along with other short and long-chain PFAS, and severity of liver steatosis and fibrosis in MASLD among adults<sup>32</sup>, our study marks the first time that 276 277 exposure to PFHpA has been associated with MASLD in adolescents. Beyond the association 278 with histological markers of MASLD, our findings indicate that adolescents with obesity

exposed to PFHpA also exhibit alterations in plasma levels of proteins and metabolites thatsignal inflammation and dysfunction in lipid metabolism.

281 To delve deeper into the molecular mechanisms underlying PFHpA-associated MASLD, 282 we conducted in vitro experiments to examine how PFHpA affects liver metabolism using the 283 3D human liver spheroid co-culture model. Our study used single-cell transcriptomics to 284 evaluate PFHpA impact on each hepatic cell population from the liver spheroids. Our findings 285 revealed that PFHpA primarily impacts lipid metabolism, leading to a notable increase in 286 anabolic events in human primary hepatocytes, with significant hepatic lipid accumulation after 287 PFHpA exposure. Among the pathways involved in lipid metabolism in hepatocytes, the 288 'Regulation of lipid metabolism by PPAR- $\alpha$ ' and 'Fatty Acid  $\beta$ -oxidation I' pathways showed 289 the strongest activation. This suggests that PFHpA promotes hepatocyte lipogenesis likely 290 through peroxisome proliferator-activated receptor (PPAR)- $\alpha$  signaling. PPARs are members of the nuclear hormone receptor superfamily, acting as ligand-activated transcription factors<sup>33</sup>. In 291 292 the liver, PPAR- $\alpha$  plays a crucial role in regulating fatty acid oxidation, and lipid and lipoprotein metabolism<sup>34</sup>, and previous research has shown that various PFAS, including PFHpA, can 293 activate PPAR- $\alpha$  in cell lines and animal models<sup>35-37</sup>. Recently, Yang et al proposed that hepatic 294 295 lipid metabolism disruption caused by PFOA and PFOS depends on the PPAR- $\alpha$ /ACOX1 axis<sup>38</sup>. 296 Our *in vitro* analysis indicates this pathway is disrupted in hepatocytes but not immune cells. We 297 found that ACOX1 expression was upregulated and integrated the pathway 'Regulation of lipid 298 metabolism by PPAR- $\alpha$ ' in hepatocytes from spheroids exposed to PFHpA. In contrast, while 299 PPAR- $\alpha$  signaling was also upregulated in T cells exposed to PFHpA, ACOX1 was not 300 differentially expressed and no lipid biosynthesis pathways were detected (Excel Supplement B).

301 Our findings indicate that PFHpA alter signaling of PPAR- $\alpha$ /ACOX1 axis in hepatocytes but not 302 T cells, to instigate abnormal hepatic lipid metabolism in humans.

- 303 Leveraging a novel statistical approach, we integrated *in vivo* and *in vitro* datasets to identify the
- 304 proteomic and metabolomic signatures that could be used as potential indicators of PFHpA-
- 305 induced MASLD. LUCID analysis was then applied to investigate whether these PFHpA-derived
- 306 OMICs biomarkers correlated with disease outcome. Notably, our analysis revealed that the
- 307 proteomic signature exhibited a stronger correlation between PFHpA exposure and MASLD risk
- 308 compared to the metabolomic signature.
- 309 In addition to establishing a clear connection between PFHpA exposure and MASLD disease in
- 310 humans, our study elucidated the intricate molecular mechanisms by which PFHpA impacts liver
- 311 metabolism. Moreover, we developed a translational research framework that allows us to
- 312 identify individuals at high risk of MASLD due to PFHpA exposure. Our framework not only
- 313 advances the current knowledge on PFAS impact on chronic liver diseases but also provides
- 314 critical information for future policies aiming at mitigating the detrimental impact of PFAS on
- 315 human health. Finally, our findings offer potential new targets for MASLD treatment strategies
- 316 by determining specific molecular targets implicated in PFAS-induced liver disease.

317

318

### 320 Methods

321

322 **Study population.** The study is based on data from the Teen-LABS study (ClinicalTrials.gov 323 number, NCT00465829), a prospective, multicenter, observational study of adolescents ( $\leq 19$ 324 years of age) who underwent bariatric surgery from 2007 through 2012. The participants were 325 enrolled at five clinical centers in the United States: Cincinnati Children's Hospital Medical 326 Center (Cincinnati, Ohio), Nationwide Children's Hospital (Columbus, Ohio), the University of 327 Pittsburgh Medical Center (Pittsburgh, Ohio), Texas Children's Hospital (Houston, Texas) and the Children's Hospital of Alabama (Birmingham, Alabama)<sup>27</sup>. Study inclusion criteria included 328 329 (1) adolescents up to age 19, (2) adolescents approved for bariatric surgery, (3) agreement to 330 participate in the Teen-LABS study, demonstrated through the signing of Informed Consent/Assent<sup>27</sup>. The Teen-LABS steering committee, which included a site principal 331 332 investigator from each participating center, worked in collaboration with the data coordinating 333 center and project scientists from the National Institute of Diabetes and Kidney Disease (NIH-334 NIDDK) to design and implement the study<sup>27</sup>. All bariatric procedures were performed by 335 surgeons who were specifically trained for study data collection (Teen-LABS-certified surgeons)<sup>27,39-41</sup>. The present study includes 136 participants with plasma collected at the time of 336 337 surgery. The study protocol, assent/consent forms, and data and safety monitoring plans were 338 approved by the Institutional Review Boards of each institution and by the independent data and safety monitoring board prior to study initiation<sup>27</sup>. Written informed consent or assent, as 339 appropriate for age, was obtained from all parents/guardians and adolescents<sup>27</sup>. Additionally, the 340 341 study was approved by the University of Southern California review board.

**Data collection.** Standardized methods for data collection have been described previously<sup>27,39-41</sup>. 343 344 Fasting blood specimens were drawn at the preoperative visit. Liver histology and liver biopsy methodology has been previously detailed<sup>41</sup>, however, briefly, liver biopsies were obtained by 345 346 core needle technique after induction of anesthesia and before performing the bariatric surgery 347 procedure. Due to the observational study design and lack of published consensus on whether 348 intra-operative liver biopsies should be standard of care at time of bariatric surgery, the decision 349 to perform a liver biopsy was deferred to the surgical teams at each site. Accordingly, 99% of all 350 biopsies were performed at the sites where intraoperative biopsy was standard of care. Liver 351 biopsy specimens were stained with hematoxylin-eosin and Masson's trichrome stains and 352 reviewed and scored centrally by an experienced hepatopathologist using the validated MASH Clinical Research Network scoring system<sup>42</sup>. MASLD was defined by the histopathological 353 354 diagnosis. Detailed descriptions of study methods, comorbidity and other data definitions, case report forms, and laboratory testing are included in previous publications<sup>27,39,40</sup>. For this analysis, 355 356 covariates, including participants' age, sex assigned at birth, race, and parents' income, were obtained at the time of surgery with trained study personnel<sup>27,39</sup>. Collected data were maintained 357 358 in a central database by the data coordinating center.

359

Plasma-PFAS Laboratory Analysis. The samples were transported on dry ice with temperature logging by World Courier (AmerisourceBergen Corporation, Conshohocken, PA), and stored at -80°C until analysis. The samples were analyzed by on-line solid phase extraction followed by LC-MS/MS as previously described<sup>43,44</sup>. The LOD was 0.03 ng/mL for all the reported compounds. Values below the LOD were imputed as ½ LOD. The batch imprecision for the quality controls was better than 6%.

366

367 **Plasma Metabolomics.** Untargeted plasma metabolomics were measured in plasma samples 368 collected at the time of bariatric surgery. Liquid chromatography coupled with high-resolution mass spectrometry methods (LC-HRMS) was used as described in Liu, et al.,45 with dual column 369 370 and dual polarity approaches and both positive and negative electrospray ionization. This 371 resulted in four analytical configurations: reverse phase (C18) positive, C18 negative, 372 hydrophilic interaction (HILIC) positive, and HILIC negative. Unique features were identified 373 using mass-to-charge ratio (m/z), retention time, and peak intensity. Features were adjusted for batch variation<sup>46</sup> and excluded if they were detected in < 20% of samples or if there was a > 30%374 375 coefficient of variability of the quality control samples after batch correction. After processing, 376 there were 3,716 features from the C18 negative mode, 5,069 from the C18 positive mode, 7,444 377 from the HILIC negative mode, and 6,944 from the HILIC positive mode, for a total of 23,173 378 features included in the analyses. The raw intensity values from LC-HRMS were scaled to a 379 standard normal distribution and  $\log_2$  transformed. Details of the analytical process have been described previously<sup>47</sup>. Confirmed annotations with confidence level 1 were available for 358 380 metabolomic features<sup>48</sup>. Metabolites were identified by comparing them to authentic chemical 381 382 standards under identical analytical conditions, and peaks were matched to annotations using m/z 383 and retention time. In instances where multiple annotations were possible due to more than one 384 molecule having retention times within the allowable error, the annotation with the closest 385 retention time to the known standard was chosen. Measured m/z and retention times, theoretical 386 m/z and retention times, adduct, possible annotations, and additional analytical details are listed 387 in Excel Supplement A.

389	Plasma Proteomics. Proteins were measured in fasting plasma samples using the proximity
390	extension array (PEA) method from Olink Explore 384 Cardiometabolic panel and Olink
391	Explore 384 Inflammation panel <sup>49</sup> . These panels measure the relative abundance of 731 proteins,
392	reported as normalized protein expression (NPX) levels after log <sub>2</sub> transformation <sup>50</sup> . After
393	excluding proteins with over 50% of observations below the limit of detection (LOD) and
394	duplicate proteins, we retained 702 proteins from the initial 731 offered after processing.
395	
396	Liver spheroid assay. We used the 3D InSight <sup>TM</sup> Human Liver Model (MT-02-302-04,
397	InSphero Inc.) to test the impact of PFHpA on human liver metabolism. This model is composed
398	of human primary hepatocytes from 10 donors (5 male and 5 female), and non-parenchymal cells
399	from 1 donor. PFHpA (CAS#375-85-9, Sigma-Aldrich, cat# 342041) stock solution was
400	prepared in dimethylsulfoxide (DMSO, Sigma-Aldrich). The final working solution was diluted
401	in lean spheroid media (CS-07-305B-01, InSphero Inc.) to a final non-cytotoxic concentration of
402	$20\mu M$ of PFHpA and 0.1% DMSO <sup>51</sup> . Liver spheroids were continuously exposed to PFHpA for
403	7 days, and culture media was replaced every 2-3 days by media containing fresh diluted
404	PFHpA. For control, liver spheroids were exposed to 0.1% DMSO diluted in lean spheroid
405	media cultured for 7 days following the same regimen of media replacement. Spheroids were
406	cultured in a 96-well format, with a single spheroid per well, under sterile conditions and
407	incubated at 37°C, 5% CO <sub>2</sub> following instructions provided by the manufacturer. We used 96
408	spheroids per condition.

410 Lipid accumulation assay and analysis. After 7 days of treatment, spheroids were fixed with 411 4% paraformaldehyde in phosphate-buffered saline (PBS) for 1h, permeabilized with 0.2% 412 Triton-413 X100 in PBS for 30 min and blocked with 1% bovine serum albumin (BSA) in PBS for 1h at 414 room temperature. Then, spheroids were stained with Nile Red ( $1\mu g/mL$ ) and DAPI ( $2\mu g/mL$ ) in 415 1% BSA/PBS for 30 min and washed 3x with PBS. Spheroids were mounted with Prolong Gold 416 Mounting Medium (Invitrogen) and images were acquired using a Leica TCS SP8 confocal 417 microscope. Lipid accumulation quantification was performed using ImageJ<sup>52</sup>. 418 419 Single-cell RNA library preparation, sequencing, and data analysis. Spheroids were 420 dissociated using 0.25% trypsin for 15 min and dead cells were removed by Dead Cell Removal 421 Kit (Miltenyi Biotech). Viable cells were partitioned with Chromium Next GEM Single Cell 3 422 Kit (10X Genomics). Libraries were sequenced at the USC Molecular Genomics Core using the 423 Illumina platform. Raw data was processed using the Cell Ranger count pipeline (10X 424 Genomics), with low-quality cell removal according to sample-specific quality control (QC) using the R package Seurat<sup>53</sup>. Comparison between PFHpA-treated and control samples was 425 426 performed by integrating samples into a unified data set using the SCTransform integration workflow implemented in Seurat<sup>54</sup>. Cell annotation was based on the expression of known cell 427 428 type marker genes. Differentially expressed genes between clusters from treatment groups were 429 detected using the Wilcoxon Rank Sum test in the Seurat FindMarkers and genes with a 430 Bonferroni adjusted p-value < 0.1 were considered significant. Biological data interpretation was performed using Ingenuity Pathways Analysis (IPA)<sup>55</sup>. 431

433	Multi-omics data integration. We performed knowledge-driven integration of the differentially
434	expressed genes obtained from transcriptomic PFHpA/liver spheroids in vitro assay (GEX), and
435	the plasma proteomics (PWAS) and metabolomics (MWAS) data obtained from the Teen-LABS
436	cohort using the online platform OmicsNet 2.0 ( <u>www.omicsnet.ca</u> ) <sup>56</sup> . Briefly, OmicsNet
437	identified the significant canonical pathways in each dataset and further separately overlapped
438	the results from GEX and PWAS, and GEX and MWAS. We then identified the proteins and
439	metabolites part of the overlapped pathways and used them as Omics signatures for further
440	analysis using LUCID.
441	
442	Statistical Analysis
443	Plasma-PFHpA and MASLD

444 Plasma concentrations of PFAS measured in Teen-LABS participants has been previously published<sup>23</sup>. We first evaluated the associations of 8 plasma-PFAS with MASLD (yes/no) using 445 446 logistic regression and controlling for multiple comparisons via a Bonferroni correction. The 447 plasma-PFAS concentrations were log2 transformed. PFHpA was the only congener found to be 448 associated with MASLD in our study; we therefore focused subsequent analyses on further 449 exploring the association between plasma-PFHpA and MASLD and its features using either 450 multinomial logistic regression models or logistic regression models, based on the number of 451 categories in each outcome. The outcomes of interest included progression of MASLD (No 452 MASLD, MASL not MASH, MASH; multinomial regression), hepatocellular ballooning (none, 453 few, many; multinomial logistic regression), grade of steatosis (none, 5-33%, 34-67%; 454 multinomial logistic regression), fibrosis (none, present; logistic regression), and MAS activity 455 score (none, 1, 2,  $\geq$ 3; multinomial logistic regression). For all models, we adjusted for

456	participants' age, race, sex assigned at birth, parents' annual income, and site of medical center.
457	To test the concentration dependent-relationship between plasma-PFHpA and MASLD, we
458	performed a generalized additive model with a low rank thin plate spline. The continuous
459	PFHpA concentration was categorized by octiles to mitigate the influence of extremely high
460	exposures while maintaining a readily interpretable dose-response relationship.

461

#### 462 Metabolome-wide association study (MWAS)—linking PFHpA exposure with disease

463 *pathways* 

464 To perform the metabolome-wide analysis study, we included confirmed annotations with confidence level 1 metabolomic features<sup>48</sup>. The log-transformed metabolite intensity as included 465 466 as the dependent variables and the log-transformed PFHpA concentration as the independent 467 variable in a multiple linear regression model. We adjusted for participants' age, race, sex 468 assigned at birth, parents' annual income, and site of medical centers to control for potential 469 confounding. As we are not primarily interested in strict metabolite identification, we conducted 470 an over-representation analysis for metabolites that were altered by PFHpA exposure (nominal p 471 < 0.05) using canonical pathways and diseases and biofunctions curated from Qiagen Knowledge 472 Base using QIAGEN Ingenuity Pathway Analysis (IPA, Qiagen Inc.). For IPA results (Fig. 3), 473 we included the pathways with the number of enriched metabolites larger than or equal to five 474 and kept the pathway with the lowest *p*-value in each category. As a result, nine pathways 475 remained and were reported in the current analysis. Then, we used a liberal threshold of nominal 476 p < 0.2 to select the metabolites entering the downstream OmicsNet step in order to include all 477 possible putative metabolites that were involved in the underlying mechanisms.

478

### 479 Proteome-wide association study (PWAS)—linking PFHpA exposure with disease pathways

480 To perform the proteome-wide analysis study, we included the NPX levels as dependent 481 variables and the log-transformed PFHpA concentration as the independent variable in a multiple 482 linear regression model. We adjusted for participants' age, race, sex assigned at birth, parents' 483 annual income, and site of medical centers to control for potential confounding. For proteins that 484 were differentially expressed by PFHpA exposure (nominal p < 0.05), we conducted the over-485 representation analysis by QIAGEN Ingenuity Pathway Analysis (IPA, Qiagen Inc.) for 486 canonical pathways and diseases and biofunctions curated from Qiagen Knowledge Base. For 487 IPA results (Fig. 3), we included the pathways with the number of enriched metabolites larger 488 than or equal to five and kept the pathway with the lowest *p*-value in each category. In addition, 489 as IPA yielded more pathways for PWAS than MWAS, we also used the absolute value of Z-490 score > 2 as a cutoff. As a result, ten top pathways with the lowest *p*-values were reported in the 491 current analysis. Then, we used a threshold of nominal p < 0.2 to select the proteins entering the 492 downstream OmicsNet step in order to include all possible proteins that were involved in the 493 underlying mechanisms.

494

495 Multi-omics integration- Latent Unknown Clustering by Integrating multi-omics Data
496 (LUCID)

497 Latent Unknown Clustering by Integrating multi-omics Data (LUCID) is a novel quasi-

498 mediation analysis approach of multi-omics data that estimates the joint associations between the

499 environmental exposure *E* (PFHpA), the multi-omics data *Z* (19 metabolites and 6 proteins that

- 500 were identified through prior pre-screening procedures), and the outcome Y (MASLD) if
- 501 supervised via the latent cluster variable *X*. The Expectation-Maximization (EM) algorithm is

502 implemented to iteratively estimate X and update the parameters until convergence. For an 503 unsupervised LUCID model, parameters of interest include (1)  $\beta$ , representing PFHpA-to-cluster 504 associations; (2)  $\mu$ , representing the cluster-specific means of omics features; and (3), the 505 individual level Inclusion probability (IP) to each latent cluster. In the unsupervised LUCID 506 approach, X integrates information from both E and Z, effectively delineating distinct risk 507 profiles among subjects. The original LUCID framework was initially proposed for early 508 integration of multi-omics data, entailing the concatenation of all omics layers into a single 509 matrix. Detailed descriptions of the original LUCID have been previously introduced<sup>26</sup>. As an 510 extension of the original LUCID, LUCID in parallel utilizes a intermediate integration strategy 511 of the multi-omics data to estimate separate latent clusters X within each omic layer by assuming no correlations across different omics layers<sup>57</sup>. In our study, there were 2 layers of multi-omics 512 513 data Z, metabolites and proteins, resulting in two individually estimated latent cluster variables, 514  $X_{\text{metabolome}}$  and  $X_{\text{proteome}}$ . We fitted the optimal unsupervised LUCID in parallel model using 515 PFHpA as *E* and pre-selected 19 metabolites and 6 proteins as *Z*. Based on model selection 516 procedures using Bayesian information criterion (BIC), the number of latent clusters per omic layer of the optimal model was chosen to be 2. We extracted the IPs to  $X_{\text{metabolome}}$  and 517  $X_{\text{proteome}}$  ( $IP_{\text{metabolome}}$  and  $IP_{\text{proteome}}$ ) from the converged optimal LUCID in parallel model. 518 *IP*<sub>metabolome</sub> and *IP*<sub>proteome</sub> are continuous probabilities indicating the likelihood of being 519 520 included in each level of cluster  $X_{\text{metabolome}}$  and  $X_{\text{proteome}}$ , respectively. These probabilities 521 are determined by the subjects' exposure levels, as well as the presence of metabolites and proteins, respectively. In follow up analyses to explore how IP<sub>metabolome</sub> and IP<sub>proteome</sub> were 522 523 associated with the outcome of interest, MASLD, we fitted a logistic regression model using IP<sub>metabolome</sub> and IP<sub>proteome</sub> as the predictors and MASLD as the binary response variable, while 524

- 525 adjust for covariates including participants' age, race, sex assigned at birth, parents' annual
- 526 income, and site of medical centers.

# 527 Data availability

- 528 Raw and processed scRNA-seq datasets were deposited into the NCBI GEO database under the
- 529 accession number GSE253186.

# 545 **References**

- 5461Rinella, M. E. *et al.* A multisociety Delphi consensus statement on new fatty547liver disease nomenclature. *Hepatology* 78, 1966-1986 (2023).548https://doi.org:10.1097/HEP.00000000000520
- 549 2 Chan, W. K. *et al.* Metabolic Dysfunction-Associated Steatotic Liver
  550 Disease (MASLD): A State-of-the-Art Review. *J Obes Metab Syndr* 32,
  551 197-213 (2023). <u>https://doi.org:10.7570/jomes23052</u>
- Eskridge, W. et al. Metabolic Dysfunction-Associated Steatotic Liver 552 3 Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient 553 Perspective. 554 and Physician J Clin Med 12 (2023).https://doi.org:10.3390/jcm12196216 555
- Brecelj, J. & Orel, R. Non-Alcoholic Fatty Liver Disease in Children.
   *Medicina (Kaunas)* 57 (2021). <u>https://doi.org:10.3390/medicina57070719</u>
- 58 5 Sweeny, K. F. & Lee, C. K. Nonalcoholic Fatty Liver Disease in Children.
  559 *Gastroenterol Hepatol (N Y)* 17, 579-587 (2021).
- Tidwell, J., Balassiano, N., Shaikh, A. & Nassar, M. Emerging therapeutic
  options for non-alcoholic fatty liver disease: A systematic review. *World J Hepatol* 15, 1001-1012 (2023). https://doi.org:10.4254/wjh.v15.i8.1001
- Yugar, L. B. T. *et al.* The efficacy and safety of GLP-1 receptor agonists in
  youth with type 2 diabetes: a meta-analysis. *Diabetol Metab Syndr* 16, 92
  (2024). <u>https://doi.org:10.1186/s13098-024-01337-5</u>
- Cusi, K. et al. American Association of Clinical Endocrinology Clinical 8 566 Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty 567 Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-568 Sponsored by the American Association for the Study of Liver Diseases 569 (AASLD). Endocr Pract 528-562 570 28. (2022).https://doi.org:10.1016/j.eprac.2022.03.010 571
- Yanai, H., Adachi, H., Hakoshima, M., Iida, S. & Katsuyama, H. MetabolicDysfunction-Associated Steatotic Liver Disease-Its Pathophysiology,
  Association with Atherosclerosis and Cardiovascular Disease, and
  Treatments. *Int J Mol Sci* 24 (2023). https://doi.org:10.3390/ijms242015473
- 576 10 Cano, R. *et al.* Role of Endocrine-Disrupting Chemicals in the Pathogenesis
  577 of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review. *Int J Mol*578 *Sci* 22 (2021). https://doi.org:10.3390/ijms22094807
- 579 11 Wahlang, B. *et al.* Toxicant-associated steatohepatitis. *Toxicol Pathol* 41, 343-360 (2013). <u>https://doi.org:10.1177/0192623312468517</u>
- Wahlang, B. *et al.* Mechanisms of Environmental Contributions to Fatty
  Liver Disease. *Curr Environ Health Rep* 6, 80-94 (2019).
  <u>https://doi.org:10.1007/s40572-019-00232-w</u>

Panieri, E., Baralic, K., Djukic-Cosic, D., Buha Djordjevic, A. & Saso, L.
PFAS Molecules: A Major Concern for the Human Health and the Environment. *Toxics* 10 (2022). <u>https://doi.org:10.3390/toxics10020044</u>

- 587 14 Calafat, A. M. *et al.* Legacy and alternative per- and polyfluoroalkyl
  588 substances in the U.S. general population: Paired serum-urine data from the
  589 2013-2014 National Health and Nutrition Examination Survey. *Environ Int*590 131, 105048 (2019). https://doi.org:10.1016/j.envint.2019.105048
- 591 15 U.S. Centers for Disease Control and Prevention. Fourth National Report on
   592 Human Exposure to Environmental Chemicals. Updated Tables March 2018
- Wang, Y. *et al.* A review of sources, multimedia distribution and health risks
  of novel fluorinated alternatives. *Ecotoxicol Environ Saf* 182, 109402
  (2019). https://doi.org:10.1016/j.ecoenv.2019.109402
- Sunderland, E. M. *et al.* A review of the pathways of human exposure to
  poly- and perfluoroalkyl substances (PFASs) and present understanding of
  health effects. J Expo Sci Environ Epidemiol 29, 131-147 (2019).
  https://doi.org:10.1038/s41370-018-0094-1
- 18 Fenton, S. E. et al. Per- and Polyfluoroalkyl Substance Toxicity and Human 600 Health Review: Current State of Knowledge and Strategies for Informing 601 Research. Toxicol 602 Future Environ Chem **40**. 606-630 (2021).https://doi.org:10.1002/etc.4890 603
- 60419Wang, P. et al. Adverse Effects of Perfluorooctane Sulfonate on the Liver605and Relevant Mechanisms.Toxics10(2022).606https://doi.org:10.3390/toxics10050265
- 607 20 Goodrich, J. A. *et al.* Exposure to perfluoroalkyl substances and risk of 608 hepatocellular carcinoma in a multiethnic cohort. *JHEP Rep* **4**, 100550 609 (2022). <u>https://doi.org:10.1016/j.jhepr.2022.100550</u>
- Liu, Y. *et al.* Occurrence and distribution of per- and polyfluoroalkyl
  substances (PFASs) in human livers with liver cancer. *Environ Res* 202,
  111775 (2021). <u>https://doi.org:10.1016/j.envres.2021.111775</u>
- Costello, E. *et al.* Exposure to per- and Polyfluoroalkyl Substances and
  Markers of Liver Injury: A Systematic Review and Meta-Analysis. *Environ Health Perspect* 130, 46001 (2022). <u>https://doi.org:10.1289/EHP10092</u>
- 61623Baumert, B. O. *et al.* Paired Liver:Plasma PFAS Concentration Ratios from617Adolescents in the Teen-LABS Study and Derivation of Empirical and Mass618Balance Models to Predict and Explain Liver PFAS Accumulation. *Environ*619SciTechnol57,620https://doi.org:10.1021/acs.est.3c02765
- 621 24 Sen, P. *et al.* Exposure to environmental contaminants is associated with
  622 altered hepatic lipid metabolism in non-alcoholic fatty liver disease. J
  623 *Hepatol* 76, 283-293 (2022). <u>https://doi.org:10.1016/j.jhep.2021.09.039</u>

- Ducatman, A. & Fenton, S. E. Invited Perspective: PFAS and Liver Disease:
  Bringing All the Evidence Together. *Environ Health Perspect* 130, 41303
  (2022). <u>https://doi.org:10.1289/EHP11149</u>
- Peng, C. *et al.* A latent unknown clustering integrating multi-omics data
  (LUCID) with phenotypic traits. *Bioinformatics* 36, 842-850 (2020).
  https://doi.org:10.1093/bioinformatics/btz667
- Inge, T. H. *et al.* Teen-Longitudinal Assessment of Bariatric Surgery:
  methodological features of the first prospective multicenter study of
  adolescent bariatric surgery. *J Pediatr Surg* 42, 1969-1971 (2007).
  https://doi.org:10.1016/j.jpedsurg.2007.08.010
- Ku, Y. *et al.* Serum Half-Lives for Short- and Long-Chain Perfluoroalkyl
  Acids after Ceasing Exposure from Drinking Water Contaminated by
  Firefighting Foam. *Environ Health Perspect* **128**, 77004 (2020).
  https://doi.org:10.1289/EHP6785
- Yang, Y. et al. In-situ fabrication of a spherical-shaped Zn-Al hydrotalcite 29 638 with BiOCl and study on its enhanced photocatalytic mechanism for 639 perfluorooctanoic acid removal performed with a response surface 640 Hazard 641 methodology. Mater 399. 123070 (2020).Jhttps://doi.org:10.1016/j.jhazmat.2020.123070 642
- Wuan, Y., Feng, L., Xie, N., Zhang, L. & Gong, J. Rapid photochemical decomposition of perfluorooctanoic acid mediated by a comprehensive effect of nitrogen dioxide radicals and Fe(3+)/Fe(2+) redox cycle. *J Hazard Mater* 388, 121730 (2020). https://doi.org:10.1016/j.jhazmat.2019.121730
- Gong, C., Sun, X., Zhang, C., Zhang, X. & Niu, J. Kinetics and quantitative
  structure-activity relationship study on the degradation reaction from
  perfluorooctanoic acid to trifluoroacetic acid. *Int J Mol Sci* 15, 14153-14165
  (2014). <u>https://doi.org:10.3390/ijms150814153</u>
- Bavid, N. *et al.* Associations between perfluoroalkyl substances and the
   severity of non-alcoholic fatty liver disease. *Environ Int* 180, 108235 (2023).
   <u>https://doi.org:10.1016/j.envint.2023.108235</u>
- 654 33 Tyagi, S., Gupta, P., Saini, A. S., Kaushal, C. & Sharma, S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various 655 diseases. Adv Pharm Technol Res 236-240 (2011). 656 J2. https://doi.org:10.4103/2231-4040.90879 657
- Reddy, J. K. & Hashimoto, T. Peroxisomal beta-oxidation and peroxisome
  proliferator-activated receptor alpha: an adaptive metabolic system. *Annu Rev Nutr* 21, 193-230 (2001). https://doi.org:10.1146/annurev.nutr.21.1.193
- Wolf, C. J., Takacs, M. L., Schmid, J. E., Lau, C. & Abbott, B. D.
  Activation of mouse and human peroxisome proliferator-activated receptor
  alpha by perfluoroalkyl acids of different functional groups and chain

- 664
   lengths.
   Toxicol
   Sci
   106,
   162-171
   (2008).

   665
   <a href="https://doi.org:10.1093/toxsci/kfn166">https://doi.org:10.1093/toxsci/kfn166</a>
   106,
   162-171
   (2008).
- Rosen, M. B. *et al.* PPARalpha-independent transcriptional targets of
  perfluoroalkyl acids revealed by transcript profiling. *Toxicology* 387, 95-107
  (2017). https://doi.org:10.1016/j.tox.2017.05.013
- Wolf, C. J., Schmid, J. E., Lau, C. & Abbott, B. D. Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPARalpha) by perfluoroalkyl acids (PFAAs): further investigation of C4-C12 compounds. *Reprod Toxicol* 33, 546-551 (2012).
  https://doi.org:10.1016/j.reprotox.2011.09.009
- 4 38 Yang, W. *et al.* PPARalpha/ACOX1 as a novel target for hepatic lipid
  metabolism disorders induced by per- and polyfluoroalkyl substances: An
  integrated approach. *Environ Int* **178**, 108138 (2023).
  https://doi.org:10.1016/j.envint.2023.108138
- Inge, T. H. *et al.* Perioperative outcomes of adolescents undergoing bariatric
  surgery: the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study. *JAMA Pediatr* 168, 47-53 (2014).
  https://doi.org:10.1001/jamapediatrics.2013.4296
- Inge, T. H. *et al.* Weight Loss and Health Status 3 Years after Bariatric
  Surgery in Adolescents. *N Engl J Med* 374, 113-123 (2016).
  https://doi.org:10.1056/NEJMoa1506699
- Kanthakos, S. A. *et al.* High Prevalence of Nonalcoholic Fatty Liver Disease
  in Adolescents Undergoing Bariatric Surgery. *Gastroenterology* 149, 623634 e628 (2015). <u>https://doi.org:10.1053/j.gastro.2015.05.039</u>
- Kleiner, D. E. *et al.* Design and validation of a histological scoring system
  for nonalcoholic fatty liver disease. *Hepatology* 41, 1313-1321 (2005).
  <u>https://doi.org:10.1002/hep.20701</u>
- Haug, L. S., Thomsen, C. & Becher, G. A sensitive method for
  determination of a broad range of perfluorinated compounds in serum
  suitable for large-scale human biomonitoring. *J Chromatogr A* 1216, 385393 (2009). <u>https://doi.org:10.1016/j.chroma.2008.10.113</u>
- Eryasa, B. *et al.* Physico-chemical properties and gestational diabetes predict transplacental transfer and partitioning of perfluoroalkyl substances. *Environ Int* 130, 104874 (2019). <u>https://doi.org:10.1016/j.envint.2019.05.068</u>
- Liu, K. H. *et al.* Reference Standardization for Quantification and
  Harmonization of Large-Scale Metabolomics. *Anal Chem* 92, 8836-8844
  (2020). <u>https://doi.org:10.1021/acs.analchem.0c00338</u>
- 46 Luan, H., Ji, F., Chen, Y. & Cai, Z. statTarget: A streamlined tool for signal
   drift correction and interpretations of quantitative mass spectrometry-based

703omicsdata.AnalChimActa1036,66-72(2018).704https://doi.org:10.1016/j.aca.2018.08.002

- Goodrich, J. A. *et al.* Metabolic Signatures of Youth Exposure to Mixtures
  of Per- and Polyfluoroalkyl Substances: A Multi-Cohort Study. *Environ Health Perspect* 131, 27005 (2023). https://doi.org:10.1289/EHP11372
- Schymanski, E. L. *et al.* Identifying small molecules via high resolution
  mass spectrometry: communicating confidence. *Environ Sci Technol* 48,
  2097-2098 (2014). <u>https://doi.org:10.1021/es5002105</u>
- Assarsson, E. *et al.* Homogenous 96-plex PEA immunoassay exhibiting high
  sensitivity, specificity, and excellent scalability. *PLoS One* 9, e95192
  (2014). <u>https://doi.org:10.1371/journal.pone.0095192</u>
- Petrera, A. *et al.* Multiplatform Approach for Plasma Proteomics:
  Complementarity of Olink Proximity Extension Assay Technology to Mass
  Spectrometry-Based Protein Profiling. *J Proteome Res* 20, 751-762 (2021).
  <u>https://doi.org:10.1021/acs.jproteome.0c00641</u>
- 718 51 Rowan-Carroll, A. *et al.* High-Throughput Transcriptomic Analysis of
  719 Human Primary Hepatocyte Spheroids Exposed to Per- and Polyfluoroalkyl
  720 Substances as a Platform for Relative Potency Characterization. *Toxicol Sci*721 181, 199-214 (2021). <u>https://doi.org:10.1093/toxsci/kfab039</u>
- Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ:
  years of image analysis. *Nat Methods* 9, 671-675 (2012).
  <u>https://doi.org:10.1038/nmeth.2089</u>
- 72553Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating726single-cell transcriptomic data across different conditions, technologies, and727species. Nat Biotechnol 36, 411-420 (2018).728https://doi.org:10.1038/nbt.4096
- Hafemeister, C. & Satija, R. Normalization and variance stabilization of
  single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol* 20, 296 (2019). <u>https://doi.org:10.1186/s13059-019-1874-1</u>
- Kramer, A., Green, J., Pollard, J., Jr. & Tugendreich, S. Causal analysis
  approaches in Ingenuity Pathway Analysis. *Bioinformatics* 30, 523-530
  (2014). <u>https://doi.org:10.1093/bioinformatics/btt703</u>
- Zhou, G., Pang, Z., Lu, Y., Ewald, J. & Xia, J. OmicsNet 2.0: a web-based
  platform for multi-omics integration and network visual analytics. *Nucleic Acids Res* 50, W527-W533 (2022). <u>https://doi.org:10.1093/nar/gkac376</u>
- 738 57 Jia, Q., Zhao, Y., Conti, D., & Goodrich, J. . Package 'LUCIDus'. *R* 739 *Foundation*. (2023).
- 740

# **Tables and Figures**

Table 1. (	Characteristics	of Teen-	-LABS	cohort	(N=136)	5)
------------	-----------------	----------	-------	--------	---------	----

Age (years), mean (SD)	17.1 (1.5)
White, n (%)	93 (68.4%)
Female, n (%)	100 (73.5%)
Parent's income, less than \$75,000, mean (SD)	111 (81.6%)
BMI $(kg/m^2)$ , mean (SD)	53.8 (9.8)
BMI: Body Mass Index	

# **Table 2.** Refined outcomes of SLD in Teen-LABS (N=136)

	n (%)		
MASLD			
No MASLD	55 (40.4)		
MASLD	81 (59.6%)		
MASLD severity			
No MASLD	55 (40.4)		
MASLD, not MASH	51 (37.5)		
MASH	30 (22.1)		
MAFLD Activity Score (MAS)			
none	25 (18.4)		
1	41 (30.1)		
2	37 (27.2)		
≥3	33 (24.3)		
Fibrosis			
None	110 (80.9)		
Present	26 (19.1)		
Steatosis			
None	106 (77.9)		
5 - 33%	18 (13.2)		
34 - >67%	12 (8.9)		
Hepatocellular ballooning			
None	115 (84.6)		
Few	16 (11.8)		
Many	5 (3.6)		
Metabolic dysfunction-associated steatotic liver			

disease (MASLD); Steatotic liver disease (SLD); The MAS can range from 0 to 8 and is calculated by the sum of scores of steatosis (0-3), lobular inflammation (0-3) and hepatocellular ballooning (0-2).



Figure 1. Translational framework.

(a) Teen-LABS study design

(b) Human liver spheroids composed of primary hepatocytes and non-parenchymal cells (NPCs) were exposed to  $20\mu$ M PFHpA for 7 days. Culture media was changed every 2-3 days to ensure constant PFHpA presence in culture media. At the end of the culture period, spheroids were dissociated into single cells, and viable cells were partitioned using the 10x Genomics platform. Single-cell gene expression libraries were sequenced using the Illumina platform. Created with <u>BioRender.com</u>.

(c) Data integration workflow. We used the OmicsNet 2.0 platform to integrate 156 differentially expressed genes upregulated in PFHpA-exposed spheroids (GEX), 42 metabolites (MWAS), and 28 proteins (PWAS) upregulated in the plasma of MAFLD subjects (compared to non-MAFLD controls). After analyzing the overlapped pathways between GEX-MWAS and GEX-PWAS, we identified 19 metabolites and 6 proteins that will be used for further analysis. Created with <u>BioRender.com</u>



Figure 2. PFHpA exposure, histopathological determined outcomes of MASLD in the Teen-LABS study

(a) Shows the odds ratio (OR) and 95% confidence intervals (95% CIs) for the association between PFHpA (ng/mL) and histopathological determined MASLD (N=136). Multinomial logistic regression between PFHpA and severity of MASLD (No MASLD, MASL not MASH, MASH). The models controls for: age, sex, race, parental income, study site. Results are shown as log2 of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.

(b) The association between octiles of PFHpA and histopathological determined MASLD (N=136). Model adjusted for: age, sex, race, parental income, study site. Results are shown as log2 of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.

(c) The association between PFHpA and histopathological determined outcomes of SLD (N=136). Figure 1c shows the odds ratio (OR) and 95% confidence intervals (95% CIs) for the association between PFHpA (ng/mL) measured in plasma and refined outcomes of SLD. Multinomial logistic regression between PFHpA and hepatocellular ballooning, steatosis grade, and MASLD Activity Score (MAS); Logistic regression between PFHpA and presence (y/n) of fibrosis. All models adjusted for: age, sex, race, parental income, study site. Results are shown as log2 of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.





c Pathways enriched by the metabolites among PFHpA exposed adolescents





d Pathways enriched by the proteins among PFHpA exposed adolescents



### Figure 3. Omics-Wide Association Study in Teen-LABS

(a) Volcano plot showing the MWAS for PFHpA and metabolites from adolescents in Teen-LABS. Linear regression between PFHpA and metabolites (N=131) adjusting for age, sex, race, parental income, study site.

(b) Volcano plot showing the PWAS for PFHpA and proteins (N=131) from adolescents in Teen-LABS. Linear regression between PFHpA and proteins (N=131) adjusting for age, sex, race, parental income, study site.

(c) Enriched pathways from the MWAS for PFHpA and metabolites from adolescents in Teen-LABS. Linear regression between PFHpA and metabolites (N=131) adjusting for age, sex, race, parental income, study site.

(d) Enriched pathways from the PWAS for PFHpA and proteins (N=131) from adolescents in Teen-LABS. Linear regression between PFHpA and proteins (N=131) adjusting for age, sex, race, parental income, study site.



Figure 4. PFHpA exposure disturbs lipid metabolism in human liver spheroids.

(a) Integrated UMAP of control and PFHpA-exposed spheroids. We observed the presence of hepatocytes, Kupffer cells, T cells, NK cells, endothelial cells, and B cells.

(b) Differentially expressed (DE) genes detected in whole liver spheroid (global) and individual cell clusters.

(c) Canonical pathways upregulated by PFHpA in whole liver spheroids. Around 48% of the pathways uploaded by PFHpA were related to lipid metabolism, while 20% were related to amino acid metabolism. Other important pathways were related to detoxification (13.8%), energy metabolism (6.9%), protein trafficking, hormone metabolism, and cell growth and differentiation.

(d) Canonical pathways upregulated by PFHpA in T cells. Most of the pathways upregulated in T cells were related to lipid metabolism (40%) and amino acid metabolism (20%). Other pathways were related to cell death, detoxification, protein trafficking, and stress response.

(e) Canonical pathways upregulated by PFHpA in hepatocytes. Almost 45% of the pathways upregulated in hepatocytes were related to lipid metabolism, and around 18% of the pathways were related to amino acid metabolism. Other important categories upregulated were energy metabolism, protein trafficking, and carbohydrate metabolism.

(f) Upregulated pathways related to lipid metabolism in hepatocytes from spheroids exposed to PFHpA.

(g) Lipid accumulation in liver spheroids. Confocal imaging of spheroids stained with Nile Red suggests an increase in lipid accumulation (red) in cells from liver spheroids exposed to PFHpA.

(h) Digital quantification of confocal imaging using ImageJ confirms a significant increase in lipid accumulation due to PFHpA exposure. CTCF = Correlated Total Cell Fluorescence



**Figure 5.** Integration of in vitro and in vivo datasets for identification of proteomic and metabolomic signatures.

(a) Pathways commonly found in GEX (in vitro) and MWAS (in vivo) datasets. The shown pathways are composed of genes and metabolites. The majority of the pathways are related to lipid metabolism and amino acid metabolism.

(b) Pathways commonly found in GEX (in vitro) and PWAS (in vivo) datasets. The shown pathways are composed of genes and proteins. The most significant pathway is related to lipid metabolism (fatty acid degradation [-log10(FDR)= 12.97].



**Figure 6.** Multi-omics integration of PFHpA, proteomics, and metabolomics to determine clusters of individuals at high risk for MASLD (N=131).

We identified two distinct multi-omic risk profiles associated with high PFHpA exposure and higher odds of MASLD. The first omic risk profile showed an association between high PFHpA levels and increased proteins. MASLD was 7 times more likely in this PFHpA-protein risk profile. The second omic risk profile showed an association between high PFHpA and altered levels of amino acids and lipids metabolites.

(a) Shows the association of PIPS from unsupervised LUCID and MAFLD (No, Yes), N= 131. The model includes the two layers in the same model. REF = NO MASLD, model adjusted for study site, age, sex, race, parental income. The reference cluster for the proteins is the high-risk cluster and for the metabolites the reference cluster is the low-risk cluster. Results are shown as log2 of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.

(b) Demonstrates the high and low risk for MASLD groups of individuals by the clusters of metabolites and proteins. Results are shown as log2 of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.